At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 9, 2026 at 16:05 ET
Structure Therapeutics reported Q3 2026 net loss of $144.8M, wider than the $65.7M loss in Q3 2025, driven by increased R&D spending as the Phase 3 ACCOMPLISH program for aleniglipron initiates. Cash burn was $60M sequentially, leaving $1.2B in cash expected to fund operations through 2028. Key catalysts include aleniglipron supplementary data in Q4 2026 and ACCG-2671 MAD data in 1H 2027.
- Net loss of $144.8M in Q3 2026 vs $65.7M in Q3 2025
- Cash, cash equivalents and short-term investments of $1.2B as of Sep 30, 2026, down from $1.3B at Jun 30, 2026
- Phase 3 ACCOMPLISH program for aleniglipron initiated in August 2026; topline data expected in 2H 2028
- R&D expenses $134.6M in Q3 2026 vs $59.0M in Q3 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access